Halozyme (HALO) director reports planned 4,000-share sale; 10b5-1 plan used
Rhea-AI Filing Summary
Bernadette Connaughton, a director of Halozyme Therapeutics (HALO), reported sales of common stock on 09/02/2025 executed under a pre-established Rule 10b5-1 trading plan adopted on 05/29/2025. The Form 4 shows three sell transactions: 100 shares at $71.71, 2,977 shares at a weighted-average $73.618 (range $72.91–$73.89), and 923 shares at a weighted-average $74.111 (range $73.95–$74.38). After these disposals the reporting person beneficially owned 46,952 shares, held directly.
Positive
- Sales were executed under a Rule 10b5-1 trading plan, which provides an affirmative defense and signals pre-planned disposition rather than opportunistic timing
- Filing provides detailed pricing ranges and weighted-average prices, improving transparency about the executed transactions
Negative
- Director reduced direct holdings to 46,952 shares, representing a decrease in insider ownership
- Material number of shares sold (4,000 total) could be interpreted by some investors as insider monetization, though the plan was pre-established
Insights
TL;DR: Director sold shares under a 10b5-1 plan; transactions appear pre-planned and routine.
The filing documents orderly sales totaling 4,000 shares (100+2,977+923) executed on 09/02/2025 under a Rule 10b5-1 plan adopted 05/29/2025. Prices reported include a single share at $71.71 and weighted-average prices for two tranches at $73.618 and $74.111, with disclosed ranges for each weighted average. The reporters direct beneficial ownership after the transactions is 46,952 shares. The filing supplies precise price ranges and confirms the 10b5-1 plan, which reduces concerns about opportunistic timing but does not indicate intent or future transactions.
TL;DR: Insider sales were executed under a documented trading plan, consistent with governance best practices.
The disclosure indicates the director used a written 10b5-1 trading plan to execute sales on 09/02/2025, which provides affirmative defense to insider trading claims when correctly implemented. The Form 4 includes signer authorization by an attorney-in-fact. Ownership fell to 46,952 shares, and the filer provided weighted-average pricing and ranges for traceability. The filing contains the statutory disclosures required for Section 16 reporting and no amendment flags.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 100 | $71.71 | $7K |
| Sale | Common Stock | 2,977 | $73.618 | $219K |
| Sale | Common Stock | 923 | $74.111 | $68K |
Footnotes (1)
- The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1. Represents a weighted average sales price per share. The shares were sold at prices ranging from $72.91 to $73.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $73.95 to $74.38. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
